JAC Advance Access originally published online on February 12, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 545-547
© 2004 The British Society for Antimicrobial Chemotherapy
Correspondence |
False-positive extended-spectrum ß-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 ß-lactamase
1 Antibiotic Resistance Monitoring & Reference Laboratory, Specialist & Reference Microbiology Division, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT; 2 British Society for Antimicrobial Chemotherapy, 11 The Wharf, 16 Bridge Street, Birmingham B1 2JS, UK
Keywords: interpretation of ESBL test results, ceftazidime, cefotaxime, cefepime, cefpodoxime
| The first 10% of the full text of this article appears below. |
Sir,
The growing complexity of extended-spectrum ß-lactamases (ESBLs) presents new detection challenges. Until recently, the predominant ESBLs in the UK were TEM- and SHV-derived ceftazidimases, occurring mostly in Klebsiella spp. On this basis it seemed adequate to screen with ceftazidime and to perform ceftazidime–clavulanate synergy tests on Enterobacteriaceae found to be resistant. Now, however, CTX-M ESBLs are spreading and ESBLs are reaching genera, principally Enterobacter, where inducible chromosomal AmpC ß-lactamases can interfere with clavulanate synergy tests. To detect CTX-M
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Reynolds, R. Hope, L. Williams, and on behalf of the BSAC Working Parties on Resistanc Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii15 - ii28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Wiegand, H. K. Geiss, D. Mack, E. Sturenburg, and H. Seifert Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures J. Clin. Microbiol., April 1, 2007; 45(4): 1167 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Menozzi, U. Eigner, S. Covan, S. Rossi, P. Somenzi, G. Dettori, C. Chezzi, and A.-M. Fahr Two-Center Collaborative Evaluation of Performance of the BD Phoenix Automated Microbiology System for Identification and Antimicrobial Susceptibility Testing of Gram-Negative Bacteria J. Clin. Microbiol., November 1, 2006; 44(11): 4085 - 4094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Spanu, M. Sanguinetti, M. Tumbarello, T. D'Inzeo, B. Fiori, B. Posteraro, R. Santangelo, R. Cauda, and G. Fadda Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. J. Clin. Microbiol., September 1, 2006; 44(9): 3257 - 3262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. C. Potz, R. Hope, M. Warner, A. P. Johnson, D. M. Livermore, and on behalf of the London & South East ESBL Project Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England J. Antimicrob. Chemother., August 1, 2006; 58(2): 320 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sturenburg, M. Lang, M. A. Horstkotte, R. Laufs, and D. Mack Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum {beta}-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria J. Antimicrob. Chemother., November 1, 2004; 54(5): 870 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, N. Potz, M. Colman, A. Williams, D. Livermore, A. MacGowan, and on behalf of the BSAC Extended Working Party on Ba Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme J. Antimicrob. Chemother., June 1, 2004; 53(6): 1018 - 1032. [Abstract] [Full Text] [PDF]
|
|